(Q37412511)

20 August 2017

1 reference

title

TNF-alpha and its inhibitors in cancer (English)

1 reference

20 August 2017

0 references

Nidhal Ben Amor

4

0 references

author name string

Inès Zidi

series ordinal

1

1 reference

PubMed ID

19277912

20 August 2017

Souhir Mestiri

series ordinal

2

1 reference

PubMed ID

19277912

20 August 2017

Aghleb Bartegi

series ordinal

3

1 reference

20 August 2017

11 March 2009

1 reference

20 August 2017

1 reference

20 August 2017

27

1 reference

20 August 2017

185-198

1 reference

20 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s12032-009-9190-3

20 August 2017

0 references

cites work

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-009-9190-3

Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF).

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12032-009-9190-3

Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells.

21 January 2018

1 reference

12 December 2020

Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study

1 reference

12 December 2020

Increase in HLA-G1 proteolytic shedding by tumor cells: a regulatory pathway controlled by NF-kappaB inducers.

1 reference

12 December 2020

TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature

1 reference

12 December 2020

Properties of thalidomide and its analogues: implications for anticancer therapy

1 reference

12 December 2020

Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety

1 reference

12 December 2020

Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease

1 reference

12 December 2020

Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease

1 reference

12 December 2020

The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study

1 reference

12 December 2020

TNF alpha and the TNF receptor superfamily: structure-function relationship(s).

1 reference

12 December 2020

Reduction of circulating secretory phospholipase A2 levels by anti-tumor necrosis factor chimeric monoclonal antibody in patients with severe Crohn's disease. Relation between tumor necrosis factor and secretory phospholipase A2 in healthy humans an

1 reference

12 December 2020

Thalidomide and congenital abnormalities

1 reference

12 December 2020

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

12 December 2020

Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden

1 reference

12 December 2020

Suppression of in vivo tumorigenicity of human lung cancer cells by retrovirus-mediated transfer of the human tumor necrosis factor-alpha cDNA

1 reference

12 December 2020

Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer

1 reference

12 December 2020

Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists

1 reference

12 December 2020

Thalidomide as an anti-cancer agent.

1 reference

12 December 2020

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

1 reference

12 December 2020

Tumor-necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability

1 reference

12 December 2020

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

12 December 2020

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

12 December 2020

Ubiquitin signalling in the NF-kappaB pathway

1 reference

12 December 2020

Tumor necrosis factor-alpha-based gene therapy enhances radiation cytotoxicity in human prostate cancer

1 reference

12 December 2020

Recombinant human tumor necrosis factor: an efficient agent for cancer treatment.

1 reference

12 December 2020

Infliximab-induced hepatitis: absence of cross-toxicity with etanercept.

1 reference

12 December 2020

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

12 December 2020

Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity

1 reference

12 December 2020

Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.

1 reference

12 December 2020

Dual role of tumor necrosis factor-alpha in angiogenesis

1 reference

12 December 2020

Thalidomide is an inhibitor of angiogenesis

1 reference

12 December 2020

Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action.

1 reference

12 December 2020

Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis

1 reference

12 December 2020

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

12 December 2020

Signalling pathways of the TNF superfamily: a double-edged sword

1 reference

12 December 2020

Tumor necrosis factor alpha-mediated tumor regression by the in vivo transfer of genes into the artery that leads to tumors.

1 reference

12 December 2020

CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial.

1 reference

12 December 2020

Golimumab, a fully human monoclonal antibody against TNFalpha

1 reference

12 December 2020

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

1 reference

12 December 2020

Etanercept: a clinical review of current and emerging indications

1 reference

12 December 2020

Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2).

1 reference

12 December 2020

Current uses of isolated limb perfusion in the clinic and a model system for new strategies

1 reference

12 December 2020

Endoscopic ultrasound delivery of an antitumor agent to treat a case of pancreatic cancer

1 reference

12 December 2020

Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program

1 reference

12 December 2020

Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial.

1 reference

12 December 2020

TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up

1 reference

12 December 2020

Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism

1 reference

12 December 2020

Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

1 reference

12 December 2020

Recommendations for the diagnosis and treatment of latent and active tuberculosis in inflammatory joint diseases candidates for therapy with tumor necrosis factor alpha inhibitors: March 2008 update

1 reference

12 December 2020

The TNF and TNF receptor superfamilies: integrating mammalian biology

1 reference

12 December 2020

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

1 reference

12 December 2020

TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors

1 reference

12 December 2020

Advances in targeted therapy: safety of biological agents

1 reference

12 December 2020

Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients

1 reference

12 December 2020

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

1 reference

12 December 2020

Autoantibody production in anti-TNF-alpha-treated patients

1 reference

12 December 2020

Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Tumor necrosis factor: an apoptosis JuNKie?

1 reference

12 December 2020

Tumour necrosis factor-alpha as a tumour promoter

1 reference

12 December 2020

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

12 December 2020

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

1 reference

12 December 2020

Tumor necrosis factor, cancer and anticancer therapy.

1 reference

12 December 2020

Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models

1 reference

12 December 2020

Adenoviral TNF-alpha gene therapy and radiation damage tumor vasculature in a human malignant glioma xenograft

1 reference

12 December 2020

Potent inhibition of tumor necrosis factor-alpha production by tetrafluorothalidomide and tetrafluorophthalimides

1 reference

12 December 2020

Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy

1 reference

12 December 2020

Cytokines and anti-cytokines as therapeutics--an update.

1 reference

12 December 2020

Serum and cyst fluid levels of interleukin (IL) -6, IL-8 and tumour necrosis factor-alpha in women with endometriomas and benign and malignant cystic ovarian tumours.

1 reference

12 December 2020

Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease

1 reference

12 December 2020

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial

1 reference

12 December 2020

Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.

1 reference

12 December 2020

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

1 reference

12 December 2020

Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease

1 reference

12 December 2020

Certolizumab pegol for the treatment of Crohn's disease

1 reference

12 December 2020

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

1 reference

12 December 2020

Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas

1 reference

12 December 2020

Tumour necrosis factor inhibitors.

1 reference

12 December 2020

A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities

1 reference

12 December 2020

Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis

1 reference

12 December 2020

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

1 reference

12 December 2020

Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha

1 reference

12 December 2020

Multiple myeloma: the present and the future

1 reference

12 December 2020

TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility

1 reference

12 December 2020

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

12 December 2020

Crosstalk via the NF-kappaB signaling system

1 reference

12 December 2020

Biological functions of tumor necrosis factor cytokines and their receptors

1 reference

12 December 2020

[Biologic therapies in inflammatory bowel disease: anti-TNF and new therapeutic targets]

1 reference

12 December 2020

Selective targeted delivery of TNFalpha to tumor blood vessels.

1 reference

12 December 2020

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

12 December 2020

The tumor necrosis factor ligand and receptor families.

1 reference

12 December 2020

TNF-R1 signaling: a beautiful pathway

1 reference

12 December 2020

Two tumour necrosis factor receptors: structure and function.

1 reference

12 December 2020

Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha

1 reference

12 December 2020

Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

1 reference

12 December 2020

An endotoxin-induced serum factor that causes necrosis of tumors

1 reference

12 December 2020

Ubiquitin-mediated regulation of TNFR1 signaling

1 reference

12 December 2020

1 reference

12 December 2020

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

1 reference

12 December 2020

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

12 December 2020

1 reference

12 December 2020

Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat

1 reference

12 December 2020

The inhibition of TNF-alpha anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model.

1 reference

12 December 2020

Beneficial effect of treatment with a monoclonal anti-tumor necrosis factor-alpha antibody on markers of coagulation and fibrinolysis in patients with active Crohn's disease

1 reference

12 December 2020

Acute myelogenous leukaemia following etanercept therapy

1 reference

12 December 2020

Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling

1 reference

12 December 2020

The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers

1 reference

12 December 2020

Tumor vascular targeting with tumor necrosis factor alpha and chemotherapeutic drugs

1 reference

12 December 2020

The therapeutic potential of tumor necrosis factor for autoimmune disease: a mechanistically based hypothesis

1 reference

12 December 2020

Polymorphisms in tumour necrosis factor (TNF) are associated with risk of bladder cancer and grade of tumour at presentation

1 reference

12 December 2020

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

1 reference

12 December 2020

Clinical experience with infliximab therapy in 100 patients with Crohn's disease

1 reference

12 December 2020

Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?

1 reference

12 December 2020

Gli1 contributes to the invasiveness of pancreatic cancer through matrix metalloproteinase-9 activation

1 reference

12 December 2020

Effects of an anti-TNF-alpha monoclonal antibody, administered throughout pregnancy and lactation, on the development of the macaque immune system

1 reference

12 December 2020

Comparison of the efficacy of the tumour necrosis factor blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis

1 reference

12 December 2020

Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases

1 reference

12 December 2020

Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab

1 reference

12 December 2020

The comparative safety and effectiveness of TNF-alpha antagonists [corrected].

1 reference

12 December 2020

Tumor necrosis factor-alpha antagonists and neuropathy

1 reference

12 December 2020

A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer

1 reference

12 December 2020

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

1 reference

12 December 2020

Involvement of the TNF-alpha autocrine-paracrine loop, via NF-kappaB and YY1, in the regulation of tumor cell resistance to Fas-induced apoptosis.

1 reference

12 December 2020

Clinical use of anti-TNF-alpha biological agents--a guide for GPs.

1 reference

12 December 2020

Adalimumab therapy in rheumatoid arthritis

1 reference

12 December 2020

TRAIL and cancer therapy.

1 reference

12 December 2020

Anti-TNF antibodies for Crohn's disease--in pursuit of the perfect clinical trial

1 reference

12 December 2020

Anti-TNF antibodies: lessons from the past, roadmap for the future

1 reference

12 December 2020

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

12 December 2020

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

12 December 2020

An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease

1 reference

12 December 2020

Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction

1 reference

12 December 2020

A small compound that inhibits tumor necrosis factor-alpha-induced matrix metalloproteinase-9 upregulation

1 reference

12 December 2020

Tumor necrosis factor or tumor promoting factor?

1 reference

12 December 2020

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

1 reference

12 December 2020

Development of Crohn's disease following anti-tumour necrosis factor therapy (etanercept)

1 reference

12 December 2020

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

12 December 2020

10.1007/S12032-009-9190-3

Identifiers

DOI

1 reference

20 August 2017

1 reference

PubMed ID

19277912